This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van de Sande, W. W. J.
Right arrow Articles by Bakker-Woudenberg, I. A. J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van de Sande, W. W. J.
Right arrow Articles by Bakker-Woudenberg, I. A. J. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2009, p. 2005-2013, Vol. 53, No. 5
0066-4804/09/$08.00+0     doi:10.1128/AAC.01556-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin{triangledown}

Wendy W. J. van de Sande,1* Ron A. A. Mathot,2 Marian T. ten Kate,1 Wim van Vianen,1 Mehri Tavakol,1 Bart J. A. Rijnders,3 and Irma A. J. M. Bakker-Woudenberg1

Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands,1 Erasmus MC, University Medical Center Rotterdam, Department of Hospital Pharmacy, Clinical Pharmacology Unit, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands,2 Erasmus MC, University Medical Center Rotterdam, Department of Internal Medicine, Section Infectious Diseases, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands3

Received 21 November 2008/ Returned for modification 6 January 2009/ Accepted 12 February 2009

At present, voriconazole (VOR) is the drug of first choice for treating invasive pulmonary aspergillosis (IPA). However, particularly in advanced stages of disease and in the severely immunocompromised host, the mortality remains substantial. The combination of VOR with an echinocandin may improve the therapeutic outcome. We investigate here whether combining VOR and anidulafungin (ANI) in advanced IPA in transiently neutropenic rats results in a higher therapeutic efficacy. Since VOR is metabolized more rapidly in rodents than in humans, dosage adjustment for VOR is necessary to obtain an area under the plasma concentration-time curve (AUC) in rodents that is equivalent to that of humans. In this study, the pharmacokinetics of VOR and ANI in rats were elucidated, and dosage schedules were applied that produced AUCs similar to those of humans. The developed dose schedules were well tolerated by the rats, without effects on renal and hepatic functions. VOR showed excellent efficacy in early IPA (100% rat survival). In advanced IPA, VOR was less efficacious (50% rat survival), whereas a significant decrease in galactomannan concentrations in lungs and sera was found in surviving rats. ANI administered in advanced IPA resulted in 22% rat survival, and the serum concentrations of fungal galactomannan were slightly but not significantly decreased. The addition of ANI to VOR did not result in significantly increased therapeutic efficacy in advanced IPA, resulting in 67% rat survival and a significant decrease in galactomannan concentration in serum. In conclusion, VOR monotherapy is therapeutically effective in the treatment of advanced-stage IPA and superior to the use of ANI. Combining both agents does not significantly improve the therapeutic outcome.

* Corresponding author. Mailing address: Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. Phone: (31) 10-7035225. Fax: (31) 10-7033875. E-mail: w.vandesande{at}erasmusmc.nl

{triangledown} Published ahead of print on 23 February 2009.

Antimicrobial Agents and Chemotherapy, May 2009, p. 2005-2013, Vol. 53, No. 5
0066-4804/09/$08.00+0     doi:10.1128/AAC.01556-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Crandon, J. L., Banevicius, M. A., Fang, A. F., Crownover, P. H., Knauft, R. F., Pope, J. S., Russomanno, J. H., Shore, E., Nicolau, D. P., Kuti, J. L. (2009). Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults. Antimicrob. Agents Chemother. 53: 5102-5107 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»